Kornimate/medical-research-clean huggingface dataset:
epidemiology of thromboembolism disease: a cohort study

Conditions: Vascular Diseases; Embolism and Thrombosis; Phlebitis; Venous Insufficiency; Pulmonary Embolism

Summary: the purpose of this study is to determine different risk factors of thromboembolic disease. different points will be studied 1. do different types of thromboembolic disease (distal deep vein thrombosis (dvt), proximal dvt, pulmonary embolism (pe) and dvt, pe without dvt) have the same clinical significance (risk factors and prognosis) ? 2. is it necessary to obtain a detailed history of thromboembolic disease ? 3. do older patients have particular risk factors ? 4. do preventive treatments modify the level of risk factors and the clinical signs of thromboembolic disease ? 5. do predictive clinical scores have the same performance for both in and outpatients ? 6. can patients with a potential high level of thromboembolic risk (surgery, pregnancy) but no clinical thromboembolic symptoms, develop a low risk ? 7. the evolution of the disease in patients with negative or positive venous thromboembolism (vte) exploratory tests.

the optimev study is a prospective epidemiological multicenter cohort study, including in-and outpatients clinically suspected of thromboembolic disease. deep vein thrombosis is diagnosed using a duplex ultrasound examination, whereas pulmonary embolism is investigated by lung scan scintigraphy or computed helical tomodensitometry and/or duplex ultrasound examination. initial data on medical history, clinical symptoms, presence of transient and chronic risk factors, diagnosis at the end of the medical examination, diagnostic tests results, treatment (type and duration) are collected by the physician into an electronic medical record. other general medical considerations are collected (particularly on cardiovascular diseases). a phone follow up at 3 months, 1, 2 and 3 years is realised by the centre for clinical research of grenoble. all venous thromboembolism (vte) positive patients (including superficial vein thrombosis) are contacted. for each vte positive a negative one is selected (same site, same season). data on mortality, development or recurrence of vte, treatments prescribed (type + duration), major bleeding, cancer onset, cardiovascular events and venous insufficiency (leg ulcer) are collected. all these serious adverse events are documented and reviewed by an independent critical events committee.

Eligibility criteria:
inclusion criteria: * patient aged more than 18 * male or female * patients with clinical thromboembolic signs (deep vein thrombosis or pulmonary embolism) exclusion criteria: * patient less than 18 years old * patient unable to understand * patient who refused to participate

Keywords: pulmonary embolism duplex ultrasound examination recurrence
alpha lipoic acid and diabetes mellitus: potential effects on peripheral neuropathy

Conditions: Diabetic Polyneuropathy; Diabetes Mellitus, Type 2

Summary: patients with type 2 dm who are following will be enrolled into the study. two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of alpha lipoic acid (ala) administration (baseline visit) and the second at the end of the third month following initiation of ala (2nd visit).

this prospective, interventional study will be conducted at benha university hospital for 3 months. patients with type 2 dm who are following at the outpatient internal medicine \& diabetes clinics in benha univeristy hospital and are eligible to participate, will be enrolled into the study. inclusion criteria comprise the following(1) patient's agreement to participate; (2) diabetic peripheral neuropathy diagnosis (3) treatment with alpha lipolic acid (ala), had to be stable for 3 months during the study. two visits were scheduled for data collection, physical examination and laboratory testing of the patients: the first prior to initiation of ala administration (baseline visit) and the second at the end of the third month following initiation of ala (2nd visit). evaluation include: 1. full neurological evaluation including motor, sensory, ankle reflex, tests for cardiac parasympathetic action 2. nerve conduction study 3. neuromuscular ultrasound 4. hba1c 5- hdl-c\& ldl-c

Eligibility criteria:
inclusion criteria: * patient's agreement to participate * diabetic peripheral neuropathy exclusion criteria: * causes of neuropathy other than diabetes * severe renal disease * recent treatment for cancer or haematological malignancies; * presence of foot ulcers; * peripheral arterial disease ; * use of agents in the previous 3 months that could interfere with the interpretation of results, such as opiates, vitamin b compounds or antioxidants; * pregnancy * lactation
pulmonary endarterectomy guided by ct scanning for patients with chronic thromboembolic pulmonary hypertension----peact

Conditions: Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Embolism

Summary: this study is a effectiveness study of the application of high-definition enhanced computed-tomography for patients with chronic thromboembolic pulmonary hypertension(cteph).the patients with cteph was randomized into 2 groups,precise pulmonary endarterectomy group(guided by enhanced ct scanning) and traditional pulmonary endarterectomy group,the hemodynamic changes tested with right sided heart catherization from baseline to post-operative period and end-point including peri-operative deaths,follow-up mortality,follow-up parameters of ultrasonic cardiogram(ucg),right-sided heart catherization(rhc),nuclear magnetic resonance imaging(mri),cardiac pulmonary exercise test(cpet) are documented,so as to compare the prognosis between these 2 groups.


Eligibility criteria:
inclusion criteria: * definite diagnosed with chronic thromboembolic pulmonary hypertension with the right-sided cathrization and pulmonary angiography; * the computed tomography imaging implied that the location of the embolism could be reached with surgeries; exclusion criteria: * beyond the age limit described above,or combined with other severe conditions such as severe organ dysfunction and considered contraindicated for surgical therapy by the cardiac surgeons; * without the consent by the patient or his/her families; * acute pulmonary embolism; * pulmonary sarcoma; * pulmonary arteritis; * combined with cardiogenic pulmonary hypertension or idiopathic pulmonary hypertension;

Keywords: computed tomography chronic thromboembolic pulmonary hypertension pulmonary endarterectomy result randomized controlled trial
effects of forgiveness-based group psychoeducation applied to cancer survivors

Conditions: Cancer Survivors

Summary: this study aims to examine the effects of forgiveness-based group psychoeducation applied to cancer survivors on fear of cancer recurrence, forgiveness, quality of life and psychiatric symptoms.

this study was designed as a randomized controlled experimental study with a pre-test-post-test and follow-up design to examine the effects of forgiveness-based group psychoeducation on fear of cancer recurrence, forgiveness, quality of life and psychiatric symptoms of cancer survivors. the aim is to evaluate the effects of a forgiveness-based psychoeducation program on cancer survivors. after the "informed voluntary consent form" is obtained from individuals who agree to participate in the study, the introductory information form, heartland forgiveness scale, fear of relapse inventory, eortc qlq-c30 quality of life scale and brief symptom inventory will be applied. pre-tests will be applied to the sample determined by an independent statistician. then, participants will be divided into intervention and control groups by simple randomization method. face-to-face forgiveness-based psychoeducation will be applied to the intervention group in 90-minute sessions once/twice a week, totaling 6 sessions. in the last session of psychoeducation, a post-test ("introductory information form", "heartland forgiveness scale", "fear of relapse inventory", "eortc qlq-c30 quality of life scale" and "brief symptom inventory") will be administered to both the intervention and control groups. the first follow-up test of the study will be administered to both the intervention and control groups 1 month after the post-test, and the second follow-up test of the study will be administered 3 months after the post-test. after the completion of the study and the measurements, it is planned to provide forgiveness-based psychoeducation to the participants in the control group.

Eligibility criteria:
inclusion criteria: * written and verbal consent to participate in the study * understanding and speaking turkish * being over 18 years old * not having any visual, hearing or mental disabilities * having been diagnosed with cancer, treated with curative intent and having completed major treatments (surgery, radiotherapy, chemotherapy) within the last 5 years exclusion criteria: * not volunteering to participate in research * having a visual, hearing or mental disability * agreeing to participate in another psychoeducational program conducted simultaneously with the research * inability to communicate in turkish * having previously received training in forgiveness and/or coping with fear of relapse

Keywords: cancer survivors forgiveness psychoeducation fear of cancer recurrence quality of life psychiatric symptoms
upar pet/ct for preoperative staging of breast cancer patients

Conditions: Breast Cancer

Summary: the sensitivity and specificity of upar pet/ct for preoperative detection of lymph node metastases in breast cancer.

the sensitivity and specificity of upar pet/ct for detection of lymph node metastases will be tested by observer-blinded readings (two separate teams) and compared to diagnostic performance of conventional preoperative diagnostic workup procedures. the reference test will be histopathology of lymph nodes obtained by operative lymph node dissection (sn/alnd). primary end point dichotomized: +/- lymph node metastases in ipsilateral axilla.

Eligibility criteria:
inclusion criteria: * biopsy-verified breast cancer * primary tumor more than 2 cm (ultrasound or clinically) * the participants must be capable of understanding and giving full informed written consent exclusion criteria: * pregnancy * lactation/breast feeding * weight above 140 kg * treatment with neoadjuvant chemotherapy * known allergy towards the imp
thromboxane a2 and osteoarthritis

Conditions: Osteoarthritis

Summary: txa2 inhibits the expression of the primary marker of thermogenesis (ucp1) while prostacyclin (pgi2), another metabolite derived from arachidonic acid, enhances its expression. given the close relationship between the adipocyte and the chondrocyte, the study team hypothesises that thromboxane a2 controls chondrocyte formation and function and thus cartilage homeostasis. the study objectives are: i) to analyse the role of txa2 on chondrocyte differentiation in vitro, ii) to determine the association between circulating and tissue txa2 levels in a rat model of osteoarthritis, and iii) to correlate circulating and synovial fluid levels of txa2 with the development of osteoarthritis in a small human cohort. the proposed research aims to better understand the mechanisms underlying the role of lipid metabolites in chondrocyte formation and function, paving the way for the development of nutritional and pharmacological therapies to combat oa and associated metabolic disorders.


Eligibility criteria:
inclusion criteria: * presence of knee osteoarthritis with effusion, , no inflammatory disease exclusion criteria: * anticoagulant treatment * inflammatory disease
comparison of optimal endotracheal tube depth using four different formulas in children aged 1-4 years and verification with fiberoptic bronchoscopy

Conditions: Pediatric Surgical Procedures Requiring Endotracheal Intubation Under General Anesthesia

Summary: . the optimal position of the endotracheal tube (ett) within the trachea is the middle third portion, distal to the vocal cords. in addition to clinical assessments, methods such as posteroanterior chest radiography (pa-cxr) and fiberoptic bronchoscopy (fob) can be used to verify ett placement. in our study, we aim to explain the relationship between the most accurate endotracheal tube depth and various formulas by using fiberoptic bronchoscopy, with the help of four different formulas based on age, height, weight, and third finger length.the study further seeks to: 1. to identify the most accurate formula for estimating ett placement depth in the pediatric population living in turkey. 2. to reduce the potential complications that may arise from incorrect ett depth. 3. to determine which formula, when verified by fiberoptic bronchoscopy, is also consistent with auscultation findings-especially in situations where chest radiography or fiberoptic bronchoscopy may not be readily available.


Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status 1 , 2 or 3 * patients scheduled for elective surgical procedures * informed consent must be obtained from both the patient and, if applicable, their parent or guardian. exclusion criteria: * patients under 1 year old or over 4 years old * patients with tracheobronchial anomalies * patients with vertebral column anomalies * patients with a history of tracheostomy and difficult intubation * patients who do not want to be included in the study * children with finger anomalies and syndromic associations * cases requiring nasal intubation

Keywords: pediatric airway, endotracheal tube, intubation depth
empirical vs tailored therapy for h. pylori infection

Conditions: Helicobacter Pylori 23S rRNA Clarithromycin Resistance Mutation; Helicobacter Pylori Infection

Summary: we aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of helicobacter pylori (h. pylori) infection in randomized controlled trials.

empirical therapy is conventional triple therapy (proton pump inhibitor (ppi) standard dose, amoxicillin 1 g and clarithromycin 500 mg twice a day for 10 days). genotypic resistance-guided tailored therapy is the method which is chosen by dpo-pcr test. while the patients who have positive result of clarithromycin resistance receive the quadruple therapy(ppi standard dose, bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days), clarithromycin susceptible patients receive the triple therapy. h. pylori is difficult to cultivate, cultivation of h. pylori and minimum inhibitory concentration test as a resistance test method are very difficult and take a long time. recently, tailored treatment based on clarithromycin susceptibility has been proposed by dual-priming oligonucleotide-based multiplex (dpo)-pcr test. this is a method to confirm the mutation of a2142g and a2143g by pcr, which are known to be highly related to the resistance of clarithromycin 23s rrna point mutation. this test is performed only by gastric biopsy. the examination time is also short as several hours, and sensitivity and specificity are about 80-85%. antibiotic resistance of h. pylori, especially clarithromycin resistance, is a cause of major failure of its eradication, and korea 's clarithromycin resistance rate is reported to be about 37%. the eradication rate of standard triple therapy reported in korea is also unsatisfactory as antibiotic resistance rate of h. pylori increases. the ideal eradication rate for h. pylori is approximately 90%, but in the meta-analysis of the recently reported primary eradication, the overall eradication rate was 74.6% in the intention to treat analysis.

Eligibility criteria:
inclusion criteria: * patients with h. pylori who had undergone endoscopic resection for gastric neoplasm * patients with h. pylori who had diagnosed at peptic ulcer disease, malt lymphoma exclusion criteria: * history of gastrectomy * patients aged younger than 20 years or older than 80 years * history of h. pylori eradication therapies or other antibiotics therapy within a month * previous allergic reaction to the study drugs (amoxicillin, clarithromycin, metronidazole, tetracycline, and esomeprazole) * contraindication to treatment drugs * pregnant or lactating women * severe concurrent illness
xanthine oxidase and uric acid origin in preeclamptic women

Conditions: Pre-Eclampsia; Hyperuricemia

Summary: findings regarding the presence of xanthine oxidase and uric acid in different blood locations is important in preeclamptic women. we aim to detecting xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations") in pregnant women with and without diagnosis of preeclampsia. the study population will be divided into groups matching the three "locations" in order to describe and compare outcome levels.

significance - findings regarding the presence of xanthine oxidase and uric acid in different blood locations may provide a scientific basis for understanding the source of them in preeclamptic women. aim - detecting xanthine oxidase and uric acid levels in both umbilical cord artery and vein as well as maternal blood (3 "locations"). methods - samples will be collected from pregnant women with and without diagnosis of preeclampsia with blood uric acid \> 6 mg/dl. than the study population will be divided into groups matching the three "locations". the investigators will describe and compare outcome levels (including xanthine oxidase, uric acid).

Eligibility criteria:
inclusion criteria: * preeclampsia and none-preeclampsia diagnosed pregnant women. exclusion criteria: * known or reported kidney disease.

Keywords: xanthine oxidase uric acid
observation on the therapeutic effect of low-intensity transcranial ultrasound stimulation combined with upper limb virtual reality training on post-stroke depression

Conditions: Post Stroke Depression; Stroke

Summary: abstract: objective:to study whether post-stroke depression can be improved through low-intensity transcranial ultrasound stimulation combined with upper limb virtual reality training, explore its possible mechanisms, and provide new rehabilitation strategies for further treatment of post-stroke depression patients. methods:30 patients with psd were selected as the subjects, and randomly divided into sham control group and combination treatment group according to computer randomization. each group was 15 cases. the combined treatment group was subjected to litus, virtual reality upper limb training, routine medication and rehabilitation treatment. the control group only conducted virtual upper limb training, routine medication and rehabilitation treatment, and tus was a false stimulation treatment. keywords:ultrasoun,transcranial,ultrasound,stimulation,virtual reality,stroke,post-stroke depression

abbreviation：transcranial ultrasound stimulation(tus),low intensity focused ultrasound (lifu),low intensity transcranial ultrasound stimulation(litus),virtual reality(vr),post-stroke depression(psd),wolf motor function test(wfmt),patient health questionnaire-9(psq-9),hamilton depression scale(hamd),pittsburgh sleep quality index(psqi)

Eligibility criteria:
inclusion criteria: * the inclusion criteria were as follows: 1. first-time stroke patients diagnosed with ischemic stroke via imaging techniques such as ct or mri; 2. duration of the disease between 15 days and 6 months, with stable condition;age between 18 and 75 years; 3. patients without severe intellectual, language comprehension, or behavioral impairments, capable of completing scale assessments, with an mmse score of ≥24; 4. hemiplegia on one side and at least a 3rd-level seated balance, with brunnstrom stage ii or higher for the upper limb，able to perform movements with the assistance of the upper limb virtual reality training； 5. no use of antidepressant medications in the past month, with phq-9 score≥10 and hama score≥17； 6. patients who are aware of the study details and have signed the informed consent form. exclusion criteria: * the exclusion criteria were as follows: 1. patients with metallic implants in the cranium or those with a pacemaker; 2. patients with unstable conditions, multiple brain infarctions, severe heart disease, or other significant organ conditions and complications, or a history of cancer.

Keywords: stroke post stroke depression tus
a study of wrist worn accelerometers in end-stage renal disease

Conditions: Chronic Kidney Diseases; End Stage Renal Disease on Dialysis; Frailty

Summary: the kidneys are important at getting rid of toxins and excess water from the body. if they fail, then toxins and excess water builds up within the body. kidney failure is treated by either giving patients a new kidney (a transplant) or by removing the toxins and fluid from the body by the process of dialysis. the investigators' aim is to personalise the care given to patients with kidney failure, and as such, they have started measuring the fitness of patients with kidney failure, who either already require dialysis or may need dialysis in the near future. this is currently done in a number of ways including measuring how strong their grip is, assessing their walking speed and asking questions about how difficult they find certain activities. in the future, the investigators think that this will allow targeted treatments to help improve their fitness and potentially identify any problems earlier. current approaches to measuring activity and fitness have limitations and in particular may over- or underestimate the level of the physical activity. to over come these limitations, participants will be asked to wear an activity tracker (called an accelerometer) on for a week. readings from the accelerometer will be compared against the other markers of fitness and activity to see if they are comparable. it will also be noted whether patients are prepared to wear the device for 7 days (compliance).


Eligibility criteria:
inclusion criteria: 1. aged over 18 years with low clearance pre-dialysis and referred to the low clearance clinic with estimated glomerular filtration rate (egfr) less than 20 ml/min/1.73m and / or commenced on haemodialysis 2. able to give informed consent exclusion criteria: 1. significant resting tremor of any aetiology or severe parkinson's disease 2. immobile 3. arteriovenous fistulas in both arms 4. any scheduled inpatient treatment or day case treatment in next 7 days.